Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.
Publications
2 shownFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 ...
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 2
- Citations
- 1,588
- Institution
- BC Cancer Agency
External Links
Identifiers
- ORCID
- 0000-0002-3211-9722
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.